ArticleFrontiers in oncology2022
A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic Prediction.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 91 citations in OpenAlex.
- Multi-omics analysis positions DNA2 at the interface of genome integrity programs and tumor behavior in pan-cancer.Functional & integrative genomics · 2026Article
- Molecular convergence in gallbladder cancer: MEK-ERK signalling at the crossroads of oncogenic hubs and pathway cross-talks.Cancer cell international · 2026Review
- Artificial Intelligence and Prostate-Breast Cancer Biology: Recent Advances in Treatments and Perspectives - A Comprehensive Review.Health science reports · 2026Article
- The Genetic Polymorphisms of DNA Repair Gene RAD51 and Their Role as a Predictive Biomarker for Breast Cancer Risk and Response to Radiotherapy in Iraqi Women.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- The Vital Role of Long Non-coding RNA SUMO1P3 in the Regulation of Human Cancer: Current Perspectives and Future Challenges.Current topics in medicinal chemistry · 2026Review
- Integrated Global Phosphoproteomic, Bioinformatic, and Machine Learning Analysis Reveals Regulatory Networks of TOP1, TOP2A, TOP2B, and C1orf35 in Hepatocellular Carcinoma (HCC).Oncology research · 2026Article
- Systematic Pan-Cancer Analysis of the Oncogenic and Immunological Function of Stanniocalcin-1 (STC1).Current medicinal chemistry · 2026Article
- Systematic review and meta analysis of the global incidence and clinicopathological characteristics of liver metastasis in patients with cervical cancer.Discover oncology · 2025Article
- Identification of Key Biomarkers for Systemic Lupus Erythematosus Progression and Therapy Response: A Bulk RNA-Sequencing-Based Bioinformatics Study.Brain and behavior · 2025Article
- Multi-omics analysis revealed heterogeneity of AARS1 and AARS2 in pan-cancer and identified AARS1 as a potential prognostic biomarker for urologic neoplasms.Apoptosis : an international journal on programmed cell death · 2025Article
- Bridging Discovery and Treatment: Cancer Biomarker.Cancers · 2025Review
- Radiomic imaging models for predicting breast cancer prognosis based on Interleukin-18 (IL18).BMC medical imaging · 2025Article
- TIGD6 in gastric cancer: exploring its prognostic value and therapeutic potential through molecular and clinical investigations.European journal of medical research · 2025Article
- Glucose Deprivation-Induced Disulfidptosis via the SLC7A11-INF2 Axis: Pan-Cancer Prognostic Exploration and Therapeutic Validation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- CSF2RA promotes gastric cancer progression through activation of the JAK2/STAT3 signaling pathway.Journal of molecular histology · 2025Article
- FAM49B mediates tumor progression and poor prognosis of gastric cancer through activating PI3K/AKT pathway.Journal of molecular histology · 2025Article
- Mendelian Randomization and Machine Learning Reveal Immune Cell and Gene Drivers in Systemic Lupus Erythematosus.Brain and behavior · 2025Article
- Silencing of PIGU inhibits the progression of esophageal squamous cell carcinoma through the PI3K/AKT signaling pathway.Scientific reports · 2025Article
- FLNA, a disulfidptosis-related gene, modulates tumor immunity and progression in colorectal cancer.Cellular & molecular biology letters · 2025Article
- In silico and in vitro assessment of TP53, ATM, RAD51, and BAX genes in gastric cancer and their contribution to radiotherapy resistance.Hereditas · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: RAD51, a critical protein for DNA repairment, has been found to associate with multiple cancer types, but, so far, a systematic pan-cancer analysis of RAD51 has not been done yet. Methods: Data were obtained from multiple open databases and genetic alteration, gene expression, survival association, functional enrichment, stemness, mutation association, immunity association, and drug therapy association of RAD51were analyzed. A prognostic model of RAD51 for overall glioma was constructed as an example application of RAD51 as a biomarker. Results: RAD51 was overexpressed in 28 types of cancers and was associated with worse overall survival in 11 cancer types. RAD51 correlated genes were enriched in cell cycle terms. RAD51 was associated with cancer stemness, tumor mutational burden, and multiple immunomodulators in different cancer types. RAD51 expression was different across immune subtypes in 11 cancer types. RAD51 was closely associated with cancer immune microenvironments in some cancer types. Proliferating T cells was the cell type that expressed highest RAD51 across most of the cancer samples analyzed. RAD51 expression had an AUC of over 0.5 in 12 of the 23 ICB subcohorts. The Tumor Immune Dysfunction and Exclusion of 9 cancer types were different between RAD51 high and low groups. RAD51 expression showed negative correlations with the sensitivity of most drugs. A prognostic nomogram was constructed with a high confidence. Conclusion: RAD51 is a clinical valuable biomarker for multiple cancer types, regarding its potential power for diagnosis, prognosis, and therapeutic prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.